PE119099A1 - Metodo para aumentar el volumen oseo utilizando agonistas selectivos fp que no ocurren naturalmente - Google Patents
Metodo para aumentar el volumen oseo utilizando agonistas selectivos fp que no ocurren naturalmenteInfo
- Publication number
- PE119099A1 PE119099A1 PE1998000854A PE00085498A PE119099A1 PE 119099 A1 PE119099 A1 PE 119099A1 PE 1998000854 A PE1998000854 A PE 1998000854A PE 00085498 A PE00085498 A PE 00085498A PE 119099 A1 PE119099 A1 PE 119099A1
- Authority
- PE
- Peru
- Prior art keywords
- selective
- agonists
- bone volume
- increase bone
- occur naturally
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 abstract 2
- 239000000018 receptor agonist Substances 0.000 abstract 2
- 229940044601 receptor agonist Drugs 0.000 abstract 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- FYBFDIIAPRHIQS-JRSBLEPXSA-N Tiaprost Chemical compound C(\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)=C/C(O)COC=1C=CSC=1 FYBFDIIAPRHIQS-JRSBLEPXSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229950004900 alfaprostol Drugs 0.000 abstract 1
- 229960004409 cloprostenol Drugs 0.000 abstract 1
- WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 abstract 1
- 229950009951 fluprostenol Drugs 0.000 abstract 1
- 229950004738 froxiprost Drugs 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- FNAMRDZHKYQEBA-YDQNNXAVSA-N methyl (2e,5z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hepta-2,5-dienoate Chemical compound COC(=O)\C=C\C\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(Cl)=C1 FNAMRDZHKYQEBA-YDQNNXAVSA-N 0.000 abstract 1
- REFZGTXXBBUTMJ-YDQNNXAVSA-N methyl (2e,5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hepta-2,5-dienoate Chemical compound COC(=O)\C=C\C\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 REFZGTXXBBUTMJ-YDQNNXAVSA-N 0.000 abstract 1
- OZDSQCVLNUIYLN-JNAAKWLTSA-N methyl (z)-7-[(1r,2s,3r,5s)-2-[(3s)-5-cyclohexyl-3-hydroxypent-1-ynyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound COC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1C#C[C@@H](O)CCC1CCCCC1 OZDSQCVLNUIYLN-JNAAKWLTSA-N 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229950002099 tiaprost Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE AL USO DE UN AGONISTA DEL RECEPTOR FP SELECTIVO QUE PUEDE SER UN ANALOGO DE PROSTAGLANDINA DE FORMULA I, DONDE R1 ES OH, AMINA, ESTER DE 1-12 MIEMBROS; X ES (CH2)n, NH, S u O; n ES 0-3; Y ES CICLOALQUIL O UN GRUPO AROMATICO. LOS ANALOGOS DE PROSTAGLANDINA PREFERIDOS SON CLOPROSTENOL, FLUPROSTENOL, TIAPROST, ALFAPROSTOL, DELPROSTENATO, FROXIPROST, ACIDO 9,11,15-ALFA-TRIHIDROXI-16-(3-CLOROFENOXI)-OMEGA-TETRA-NORPROSTA-4-CIS-13-TRANS-DIENOICO, ENTRE OTROS. EL AGONISTA DEL RECEPTOR FP ES USADO PARA AUMENTAR EL VOLUMEN OSEO Y TRATAR UN TRASTORNO OSEO TAL COMO OSTEOPOROSIS, OSTEOARTRITIS, ENFERMEDAD DE PAGET Y FRACTURA DE HUESO. EL AGONISTA ES MAS SELECTIVO AL RECEPTOR FP EN RELACION A OTROS RECEPTORES DE PROSTAGLANDINAS EN UNA RELACION DE 1:10
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5830697P | 1997-09-09 | 1997-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE119099A1 true PE119099A1 (es) | 2000-02-03 |
Family
ID=22015996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000854A PE119099A1 (es) | 1997-09-09 | 1998-09-09 | Metodo para aumentar el volumen oseo utilizando agonistas selectivos fp que no ocurren naturalmente |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6156799A (es) |
| EP (1) | EP1045694A1 (es) |
| JP (1) | JP2001515864A (es) |
| KR (1) | KR20010023840A (es) |
| CN (1) | CN1269721A (es) |
| AR (1) | AR013479A1 (es) |
| AU (1) | AU739275B2 (es) |
| BR (1) | BR9811780A (es) |
| CA (1) | CA2303800A1 (es) |
| CO (1) | CO4980882A1 (es) |
| HU (1) | HUP0004581A2 (es) |
| ID (1) | ID24827A (es) |
| IL (1) | IL134760A0 (es) |
| NO (1) | NO20001171L (es) |
| PE (1) | PE119099A1 (es) |
| PL (1) | PL339288A1 (es) |
| SK (1) | SK3412000A3 (es) |
| TR (1) | TR200000662T2 (es) |
| WO (1) | WO1999012551A1 (es) |
| ZA (1) | ZA988228B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ513825A (en) * | 1999-03-05 | 2001-09-28 | Procter & Gamble | C 16 unsaturated FP-selective prostaglandins analogs |
| JP2002538105A (ja) * | 1999-03-05 | 2002-11-12 | ザ プロクター アンド ギャンブル カンパニー | 骨体積の増加のための天然に存在しないｅｐ１選択的アゴニストの使用 |
| EP1159265B1 (en) * | 1999-03-05 | 2004-11-24 | Duke University | C-16 unsaturated fp-selective prostaglandins analogs |
| AU3385900A (en) * | 1999-03-05 | 2000-09-21 | Procter & Gamble Company, The | Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives |
| CA2303060A1 (en) * | 1999-04-14 | 2000-10-14 | United States Gear Corporation | Towed vehicle brake controller |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US7467892B2 (en) | 2000-08-29 | 2008-12-23 | Imaging Therapeutics, Inc. | Calibration devices and methods of use thereof |
| US6904123B2 (en) | 2000-08-29 | 2005-06-07 | Imaging Therapeutics, Inc. | Methods and devices for quantitative analysis of x-ray images |
| JP4049312B2 (ja) | 2000-08-29 | 2008-02-20 | イメージング セラピューティクス，インコーポレーテッド | Ｘ線画像の定量解析法および装置 |
| US8639009B2 (en) | 2000-10-11 | 2014-01-28 | Imatx, Inc. | Methods and devices for evaluating and treating a bone condition based on x-ray image analysis |
| US7660453B2 (en) | 2000-10-11 | 2010-02-09 | Imaging Therapeutics, Inc. | Methods and devices for analysis of x-ray images |
| EP1389947B1 (en) | 2001-05-25 | 2009-08-26 | Imaging Therapeutics, Inc. | Methods to diagnose treat and prevent bone loss |
| IL159996A0 (en) * | 2001-07-23 | 2004-06-20 | Ono Pharmaceutical Co | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| CN1893977B (zh) * | 2001-07-23 | 2012-12-05 | 小野药品工业株式会社 | 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物 |
| EP1478314A2 (en) * | 2002-02-07 | 2004-11-24 | Rutgers, The State University Of New Jersey | Therapeutical polyanhydride compounds for drug delivery |
| US7840247B2 (en) | 2002-09-16 | 2010-11-23 | Imatx, Inc. | Methods of predicting musculoskeletal disease |
| US8965075B2 (en) | 2002-09-16 | 2015-02-24 | Imatx, Inc. | System and method for predicting future fractures |
| WO2004086972A2 (en) | 2003-03-25 | 2004-10-14 | Imaging Therapeutics, Inc. | Methods for the compensation of imaging technique in the processing of radiographic images |
| US8290564B2 (en) | 2003-09-19 | 2012-10-16 | Imatx, Inc. | Method for bone structure prognosis and simulated bone remodeling |
| EP1663002A4 (en) * | 2003-09-19 | 2007-11-28 | Imaging Therapeutics Inc | BONE STRUCTURE PROGNOSTIC METHOD AND SIMULATED BONE REMODELING |
| US20080058613A1 (en) * | 2003-09-19 | 2008-03-06 | Imaging Therapeutics, Inc. | Method and System for Providing Fracture/No Fracture Classification |
| CA2580726A1 (en) | 2004-09-16 | 2006-03-30 | Imaging Therapeutics, Inc. | System and method of predicting future fractures |
| US8939917B2 (en) | 2009-02-13 | 2015-01-27 | Imatx, Inc. | Methods and devices for quantitative analysis of bone and cartilage |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4621100A (en) * | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
| WO1993015767A1 (en) * | 1992-02-05 | 1993-08-19 | Merck & Co., Inc. | Implant therapy for bone growth stimulation |
| US5310759A (en) * | 1992-08-12 | 1994-05-10 | Bockman Richard S | Methods of protecting and preserving connective and support tissues |
| US5409911A (en) * | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
| US5747660A (en) * | 1995-11-06 | 1998-05-05 | The University Of Colorado | Nucleic acid encoding prostaglandin F2α receptor regulatory protein |
| US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
-
1998
- 1998-09-04 WO PCT/US1998/018338 patent/WO1999012551A1/en not_active Application Discontinuation
- 1998-09-04 JP JP2000510448A patent/JP2001515864A/ja not_active Withdrawn
- 1998-09-04 TR TR2000/00662T patent/TR200000662T2/xx unknown
- 1998-09-04 US US09/148,105 patent/US6156799A/en not_active Expired - Fee Related
- 1998-09-04 AU AU92192/98A patent/AU739275B2/en not_active Ceased
- 1998-09-04 KR KR1020007002516A patent/KR20010023840A/ko not_active Application Discontinuation
- 1998-09-04 EP EP98944718A patent/EP1045694A1/en not_active Withdrawn
- 1998-09-04 IL IL13476098A patent/IL134760A0/xx unknown
- 1998-09-04 PL PL98339288A patent/PL339288A1/xx unknown
- 1998-09-04 BR BR9811780-7A patent/BR9811780A/pt not_active IP Right Cessation
- 1998-09-04 SK SK341-2000A patent/SK3412000A3/sk unknown
- 1998-09-04 ID IDW20000637A patent/ID24827A/id unknown
- 1998-09-04 CA CA002303800A patent/CA2303800A1/en not_active Abandoned
- 1998-09-04 HU HU0004581A patent/HUP0004581A2/hu unknown
- 1998-09-04 CN CN98808885A patent/CN1269721A/zh active Pending
- 1998-09-08 AR ARP980104483A patent/AR013479A1/es unknown
- 1998-09-09 CO CO98051811A patent/CO4980882A1/es unknown
- 1998-09-09 PE PE1998000854A patent/PE119099A1/es not_active Application Discontinuation
- 1998-09-09 ZA ZA988228A patent/ZA988228B/xx unknown
-
2000
- 2000-03-07 NO NO20001171A patent/NO20001171L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ID24827A (id) | 2000-08-24 |
| EP1045694A1 (en) | 2000-10-25 |
| US6156799A (en) | 2000-12-05 |
| CO4980882A1 (es) | 2000-11-27 |
| ZA988228B (en) | 1999-03-09 |
| WO1999012551A1 (en) | 1999-03-18 |
| AU739275B2 (en) | 2001-10-11 |
| NO20001171L (no) | 2000-05-09 |
| BR9811780A (pt) | 2000-09-12 |
| IL134760A0 (en) | 2001-04-30 |
| CN1269721A (zh) | 2000-10-11 |
| PL339288A1 (en) | 2000-12-04 |
| AR013479A1 (es) | 2000-12-27 |
| JP2001515864A (ja) | 2001-09-25 |
| NO20001171D0 (no) | 2000-03-07 |
| TR200000662T2 (tr) | 2000-07-21 |
| SK3412000A3 (en) | 2000-12-11 |
| HUP0004581A2 (hu) | 2001-05-28 |
| KR20010023840A (ko) | 2001-03-26 |
| AU9219298A (en) | 1999-03-29 |
| CA2303800A1 (en) | 1999-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE119099A1 (es) | Metodo para aumentar el volumen oseo utilizando agonistas selectivos fp que no ocurren naturalmente | |
| IL122958A0 (en) | Method of identifying a calcimimetic compound | |
| EA199900756A1 (ru) | Замещенные изохинолины в качестве нервно-мышечных блокаторов ультракраткосрочного действия | |
| ES2054872T3 (es) | Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht. | |
| CO4910163A1 (es) | Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas | |
| ES2064310T3 (es) | Procedimiento para preparar compuestos de imidazopiridina. | |
| ES2135058T3 (es) | Fosfito monodentado y composicion de catalizador a base de niquel para la hidrocianacion de monoolefinas. | |
| DE69333527D1 (de) | Calciumrezeptoraktive moleküle | |
| GT199800158A (es) | Agonistas de prostaglandinas. | |
| PE46899A1 (es) | Derivados de n-fenil-sulfonamida | |
| ES2171224T3 (es) | Nuevos peptidos opioides. | |
| ES2066750T3 (es) | Metodo para la modulacion de procesos mediatizados por receptores de retinoides y compuestos de utilidad en dicho metodo. | |
| ES2155278T3 (es) | Procedimiento para producir fibra de poliester y la fibra de poliester obtenida por el mismo. | |
| AR007241A1 (es) | Analogos de 20-epi-16-eno de vitamina d3, composiciones farmaceuticas que los contienen, procedimiento para la preparacion de dichos compuestos yempleo de dichos compuestos para la preparacion de composiciones farmaceuticas | |
| CO5160251A1 (es) | Analogos de prostaglandinas selectivos del receptor fp c16 insaturados | |
| BR9810773A (pt) | Uso de um ingrediente anestésico local de ação prolongada, composição farmacêutica, uso de um anestésico local, e, kit | |
| ES2043891T3 (es) | Procedimiento para preparar nuevos agentes antiarritmicos ii. | |
| PE118899A1 (es) | Metodo para aumentar el volumen oseo | |
| ES2038641T3 (es) | Amidas del acido salicilico, procedimiento para su obtencion y su empleo. | |
| ES2179857T3 (es) | Derivados de quinoleina sustituidos, procedimiento para su preparacion y su utilizacion. | |
| ES2196084T3 (es) | Procedimiento para la obtencion de 8-alfa-oxido-13,14,15,16-tetranorlabdano. | |
| ES2097815T3 (es) | Feniletanolaminas, medicamentos que contienen estos compuestos y procedimiento para su preparacion. | |
| ES2187783T3 (es) | Derivados de indolina utiles como antagonistas del receptor 5-ht-2c. | |
| ES2138960T3 (es) | Tratamiento del fallo de la lactacion humana. | |
| TW360629B (en) | Calcium receptor active molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |